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Summary: We developed a non-competitive, enzyme-linked, immunosorbent assay (ELISA) for the quantitation
of lipoprotein lipase (LPL) in human postheparin plasma using affinity-purified antihuman milk lipoprotein lipase
antibodies produced in chicken eggs and a monoclonal antibody directed against human lipoprotein lipase. We
compared our ELISA method with a commercially available sandwich-enzyme immunoassay (Markit-F LPL EIA
Kit, Dainippon Pharmaceutical Co, Ltd. Osaka, Japan). The reference values for lipoprotein lipase catalytic activity
concentration and mass concentration in healthy Finns were determined. Lipoprotein lipase activity concentration
(mean ± SD) was 297 ± 112U/1 in women, and mass concentration as measured by the ELISA method was
1058 ± 367 g/l. The corresponding values for men were 247 ± 97 U/l and 815 ± 207 g/l, respectively. Across
the whole concentration range of the ELISA method, the control samples' intra- and inter-assay coefficients of
variation (CV) were 5.1% and 6.5%, respectively. The correlation between the ELISA and EIA methods was good,
r = +0.81. The importance of the correct standardisation of immunoassays is discussed.
Introduction
Lipoprotein lipase (EC 3.1.1.34) plays a central role in
lipoprotein metabolism by hydrolysing both dietary and
endogenous triacylglycerols transported in chylomicrons
and VLDL particles (1—3). Upon hydrolysis, fatty acids
are liberated for use in adipose and muscle tissues. Lipo-
protein lipase protein is mainly synthesised in adipose
tissue, muscles, and lactating mammary glands (4). The
mature protein is secreted from parenchymal cells and
transported to capillaries, where lipoprotein lipase is
bound to glycosaminoglycan components of the capil-
lary endothelium (5, 6).
Lipoprotein lipase can be released into the circulation
by intravenous injection of heparin, which enables the
lipoprotein lipase to be measured in postheparin plasma.
An antiserum inhibition method using glycerol tri[l-
C14]oleate as a substrate was the principle method used
to measure lipoprotein lipase activity concentration (7).
Many immunological approaches for the quantitation of
lipoprotein lipase mass concentration in plasma using
both poly- and monoclonal antibodies have been re-
ported (8—15). At present, only one commercial kit for
the quantitation of lipoprotein lipase mass concentration
in plasma is available (Markit-F LPL EIA Kit, Dainip-
pon Pharmaceutical Co, Ltd. Osaka, Japan) (15).
In metabolic studies on patients with lipid disorders, the
analysis of lipoprotein lipase activity concentration and
mass concentration are important diagnostic measure-
ments to estimate whether or not the lipid abnormalities
result from a defect in the lipoprotein lipase protein
structure. In investigating the functional abnormalities
of lipoprotein lipase enzyme in genetic dyslipidaemic
disorders, selective measurements of activity concentra-
tion and mass concentration have provided valuable data
on the synthesis and secretion of lipoprotein lipase pro-
tein in cell culture systems (16, 17).
In this report we describe the immunisation protocol for
chickens, the purification of polyclonal anti-human lipo-
protein lipase antibodies in chicken eggs, and the devel-
opment of an enzyme-linked immuno-sorbent assay
(ELISA), a non-competitive sandwich method for quan-
titation of lipoprotein lipase mass concentration in post-
heparin plasma. The present method developed is an ex-
tension to our previously described lipoprotein lipase
ELISA assay (14). In this paper we focussed on the
methodological details. We also compared our ELISA
method with a commercial, one-step sandwich EIA (15),
and determined reference values for postheparin plasma
lipoprotein lipase mass concentration and activity con-
centration in healthy Finns. This study confirms the need
for international reference materials to be compiled
among laboratories and the importance of the correct
standardisation of immunoassays.
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Methods
Pur i f i ca t ion of human mi lk l ipoprotein lipase
Step 1. Acetone-ether powder of lipoprotein lipase
Human milk was obtained from the Human Milk Bank, University
Hospital of Helsinki, and was immediately frozen at -20 °C. After
thawing, the milk was centrifuged at 10000g for 30 min, at
+ 4 °C. The fat cake was separated and delipidated according to
the protocol described by Zeclmer (17), using a sequential delipida-
tion with cold acetone and diethyl ether. The acetone-ether powder
was dried under nitrogen and stored at —20 °C before use.
Step 2. Heparin-Sepharose chromatography
Four grams of acetone-ether powder were extracted for 2 h at
+ 4 °C with 60 ml of 0.1 mol/1 NaCl, 0.05 mol/1 NHUOH/NI^Cl
(pH 8.5), containing 2 g/1 Triton N-101, 2000 IU aprotinin and 360
μg leupeptin. The mixture was centrifuged at 10 000 g for 30 min
at + 4°C. Glycerol, 100 g/1, and solid NaCl were added to the
supernatant to reach the final concentration of 0.35 mol/1 NaCl.
A heparin-Sepharose column (28 X 60 mm, 48 ml) (Pharmacia,
Uppsala, Sweden) was equilibrated with 0.35 mol/1 NaCl, 100 g/1
glycerol, 5 mmol/1 sodium barbital, pH 7.4 containing 0.5 g/1
EDTA and 0.5 g/1 NaN3. The acetone-ether extract was applied to
the column at a flow rate of 1 ml/min. The column was washed in
1 mol/1 NaCl, 100 g/1 glycerol, 5 mmol/1 sodium barbital, pH 7.4
containing 0.5 g/1 EDTA and NaN3 until the UV-absorption (A28o)
of the eluate reached the baseline. Lipoprotein lipase was eluted
from the heparin-Sepharose column with a buffer of 2 mol/1 NaCl,
100 g/1 glycerol, 5 mmol/1 sodium barbital, pH 7.4 containing 0.5
g/1 EDTA and NaN3, and 1 g/1 Triton N-101. Lipoprotein lipase
activity was measured (7), and the active fractions were combined.
Step 3. m-Aminophenylboronic acid (PEA) agarose affinity
chromatography
A PBA-agarose column (28 mm X 30 mm, 24 ml) (Sigma, St.
Louis, USA) was packed and equilibrated with 10 mmol/1 phos-
phate, 100 g/1 glycerol, l mol/1 NaCl, pH 7.5 containing 2 g/1 Triton
N-101 and 1 mmol/1 EDTA. The pool of combined active fractions
from the heparin-Sepharose column was applied onto the PBA-
column with a flow rate of 1 ml/min. Lipoprotein lipase activity
was quantitatively bound to the column as no lipoprotein lipase
activity could be measured in either the eluate or in the wash frac-
tions. Lipoprotein lipase protein was eluted with 10 mmol/1 phos-
phate, 1 mol/1 NaCl, 200 g/1 glycerol, 2 g/1 Triton N-101, 0.3 mol/1
sorbitol, pH 10, containing 1 mmol/1 EDTA and 0.1 g/1 NaN3 (19).
The fractions with lipoprotein lipase activity were pooled and
stored at -20 °C.
Step 4. Preparative gel electrophoresis
Twenty ml aliquot of /w-aminophenylboronic acid pool of lipopro-
tein lipase-active fractions were precipitated using chloroform-
methanol (20), and electrophoresis was performed on a homoge-
nous 125 g/1 SDS-polyacrylamide gel (SDS-PAGE). The protein
band was visualised with Serva blue, and the fraction correspond-
ing to a lipoprotein lipase molecular mass was dissected out and
eluted overnight with 0.1 mol/1 Tris-HCl, 0.1 mmol/1 SDS, pH 8.8
buffer in a tube roller at room temperature.
The purity of lipoprotein lipase
Samples from each purification step were analysed on a 125 g/1
SDS-PAGE gel and stained with Coomassie staining, as shown in
figure 1 A. The same samples were also tested for purity with West-
ern blot analysis using monoclonal antihuman lipoprotein lipase
antibody (Oncogene Science, New York, USA) (fig. IB).
Other methods
.SDS-PAGE was run as described by Laemmli (21). Western blot-
ting was performed according to Towbin et al. (22). Protein concen-
tration was determined with the Lowry method (23) using a human
serum albumin as a standard.
Production of polyclonal chicken egg antibodies
against lipoprotein lipase
Leghorn hens were immunised at the age of 25 weeks with an
initial dose of 50 μg of lipoprotein lipase protein emulsified in
complete Freund's adjuvant. The animals were injected intramus-
cularly, followed every second week by booster injections of 50 μg
lipoprotein lipase protein in incomplete adjuvant. The eggs began
to be collected one month after the first antigen injection.
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Purification of polyclonal antihuman lipoprotein
lipase antibodies from eggs
The purification of egg immunoglobulins was carried out as de-
scribed by Jensenius et al. (24). Briefly, the yolk was separated
from the white, diluted in Tris buffered saline (1 :4), and centri-
fuged at 2000 g for 20 min at room temperature. The supernatant
was mixed with 150 g/1 Dextran sulphate, 1 mol/1 CaCl2 in Tris
buffered saline, left to stand at room temperature for 30 min, and
centrifuged at 2000 g for 20 rain. The proteins in the supernatant
were precipitated overnight with ammonium sulphate (300 g/1) at
room temperature. The protein pellet was extracted with 15 mrnol/1
Tris-HCl, 1 mol/1 urea, pH 8.0, and solubilised proteins were run
through a DEAE-Affi-Gel Blue® column (Bio-Rad, Hercules, Cali-
fornia, USA) at a flow rate of 1.0 ml/min. After washing, the bound
antibodies were eluted with 15 mmol/1 Tris-HCl, 1 mol/1 urea, pH
8.0. The protein in elution fractions was monitored at A280.
Affinity-purification of chicken antihuman lipoprotein
lipase antibodies
A 1.0 g cyanogen bromide (CNBr)-activated Sepharose 4B (Phar-
macia, Uppsala, Sweden) column was prepared according to the
manufacturer's instructions (25). Semi-purified human milk lipo-
protein lipase protein (1 mg) was covalentiy coupled with the gel
matrix. Tlie final lipoprotein lipase affinity gel was packed into a
4 ml column.
An aliquot of 5 ml from DEAE-Affi-Gel Blue® chromatography
pool was applied through the affinity column at a flow rate of 0.5
ml/min. The column was washed with phosphate buffered saline
until the A280 reached the baseline. Immunoglobulins were released
with 0.1 mol/1 glycine, pH 2.5. The eluted fractions were immedi-
ately neutralised with l mol/1 Tris-HCl, pH 8.5. The A280 peak
fractions were pooled. Immunoglobulins were dialysed against
phosphate buffered saline and stored at -20 °C.
ELISA for quantitation of lipoprotein lipase
A polyclonal, affinity-purified, antihuman lipoprotein lipase anti-
body of chickens (5 mg/1 in carbonate buffer, pH 9.6) was bound
to microtitre plates by incubation for 4 h at -1-25 °C. The plates
were washed 6 times with phosphate buffered saline, 1 g/1 bovine
serum albumin, 0.5 g/1 Tween-20 and blocked with phosphate buf-
fered saline, 10 g/1 bovine serum albumin, 0.5 g/1 Tween-20 for
2 h at -f 37 °C. After six washes, lipoprotein lipase standards (66,
33, 16.5, 8.25, 4.1, 2.1, 1.0, and 0.5 μg/l) and lipoprotein lipase
samples were added (diluted in phosphate buffered saline, 1 g/1
bovine serum albumin, 0.5 g/1 Tween-20) and incubated at + 4 °C
for a minimum of 16 h. The wells were washed six times and mo-
noclonal antihuman-lipoprotein lipase antibody (Oncogene Sci-
ence, New York, USA) was added in a 1 : 10000 dilution in phos-
phate buffered saline, 1 g/1 bovine serum albumin, 0.5 g/1 Tween-
20 and incubated for 3 hours at room temperature. After six
washes, biotinylated affinity-purified rabbit anti-mouse antibody
(Dako A/S, Glostrup, Denmark, 1 : 4000 in phosphate buffered sa-
line, 1 g/1 bovine serum albumin, 0.5 g/1 Tween-20) was added,
and the reaction proceeded for 2 h at + 37 °C. After six washes
streptavidin-peroxidase was added (Amersham, Amersham, U. K.,
1 : 2000 in phosphate buffered saline, 1 g/1 bovine serum albumin,
0.5 g/1 Tween-20) and incubated for l h at -h 37 °C. The colour
reaction with a substrate 1.2-phenylenediamine dihydrochloride
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(Fluka Chemika, Basle, Switzerland) proceeded for 30 minutes
(protected from the light), after which the reaction was halted with
2.5 mol/1 H2SO4. Absorbance at 492 nm was recorded using
ELISA plate reader (läbsystems Multiscan MCC/340, Helsinki,
Finland).
Markit-F LPL EIA Kit
The quantitation of lipoprotein lipase was performed according to
the manufacturer's protocol (Markit-F LPL EIA Kit, Dainippon
Pharmaceutical Co, Ltd., Osaka Japan) (15). The assay is a one-
step sandwich immunoassay kit that uses two distinct monoclonal
antibodies specific for human lipoprotein lipase: One is an anti-
lipoprotein lipase monoclonal antibody linked to a bacterial cell
wall as an insolubilised monoclonal antibody, and the other is a ß-
Z)-galactosidase labelled antibody as an enzyme-linked detecting
monoclonal antibody. Lipoprotein lipase produced by THP-1 cells
(human myelogenous leukaemia cells) is used as a standard. The
fluorogenic substrate used is 4-methyl-umbelliferyl-ß-D-galacto-
pyranoside. Fluorescence intensity was measured at an excitation
of 365 nm and emission was measured at 450 nm using a Perkin
Elmer LS-5 Luminescence Spectrometer, London, U. K.
Lipoprotein lipase act ivi ty assay
Lipoprotein lipase activity concentration was measured using the
antiserum inhibition method (7).
Subjects
Sixty-six healthy Finns (38 women, 28 men) were studied. The
mean age for women was 43 ± 6 years and the mean age for men
42 ± 8 years. The volunteers did not use any medication or oral
contraceptives. Venous blood samples were drawn after an over-
night fast. For lipoprotein lipase activity concentration and lipopro-
tein lipase mass concentration measurements, venous blood was
drawn into chilled tubes containing lithium heparin 15 min after an
intra-venous injection of heparin (100 lU/kg, Huhtamäki, Leiras,
Helsinki, Finland). Postheparin plasma samples were stored at
-70 °C before the measurements.
Statistical methods
Means, standard deviations (SD), and coefficients of variation
(CV) were calculated for the lipoprotein lipase control samples.
Pearson's correlation coefficients were calculated to evaluate the
degree of linear association between variables, the significance of
which was calculated using the paired /-test procedure.
Results
The purity of lipoprotein lipase
The purity of lipoprotein lipase was assessed on a 125
g/1 SDS-PAGE, as shown in figure 1A. Samples from
the individual purification steps were analysed. The hep-
arin-Sepharose chromatography was an efficient step for
removing most of the proteins of human milk powder
(fig. 1A, lane 2). After heparin-Sepharose chromatogra-
phy, the active lipoprotein lipase pool fractions from m-
aminophenyl boronic acid agarose column contained a
major contamination protein with a relative molecular
weight of about 80000 (fig. 1A, lane 3). Separate
attempts were made to remove this protein using gel
filtration, phenyl-Sepharose chromatography, and by
using salt gradient (from 0.4 to 2 mol/1 NaCl) in heparin-
Sepharose affinity chromatography, none of which were
successful. Therefore, the lipoprotein lipase preparation
obtained after the two affinity chromatography steps was
concentrated and further purified using a preparative
125 g/1 SDS-PAGE. The final preparation contained a
major band with a relative molecular weight of 58000,
which was identified as lipoprotein lipase using mo-
noclonal anti-lipoprotein lipase antibody in immunoblot-
ting (fig. IB). This preparation was used as a calibrator
standard in the ELISA system (see further: Standardisa-
tion of the ELISA method).
During the purification steps, it is possible that human
milk lipoprotein lipase protein undergoes structural
modifications that affect its immunoreactivity. Accord-
ing to the manufacturer's instructions, the lipoprotein li-
pase protein delivered in the Markit-F LPL EIA Kit
(Dainippon Pharmaceutical C., Ltd. Osaka, Japan) has
been produced in THP-1 leukaemia cells and has shown
to be immunologically homologous with human post-
heparin plasma lipoprotein lipase (14). It is, therefore, a
good primary standard to calibrate other immunoassays
for lipoprotein lipase mass determination. To determine
the immunoreactive mass of our purified lipoprotein li-
pase, its protein concentration was measured by ELISA
using the protein delivered as a primary standard in the
Markit-F LPL EIA Kit.
Specificity of an t ihuman antibodies
The monoclonal antihuman lipoprotein lipase antibody
produced by Oncogene Science has been tested by Babi-
rak et al. (11) and has been shown to recognise an epi-
tope present in the C-terminal part of human lipoprotein
lipase (12). Specific immunoreactivity of our affinity-
purified polyclonal antihuman lipoprotein lipase anti-
body was tested with Western blot analysis. The affinity-
purified antibody reacted with human lipoprotein lipase
that was isolated from human milk or postheparin
plasma, but it did not react with human hepatic lipase,






Fig. 1 SDS-polyacrylamide gel (A) and Western blot (B) of the
samples from each purification step of the lipoprotein lipase pro-
tein.
Lane 1 = delipidated human milk protein in buffer,
lane 2 = pool of lipoprotein lipase active fractions from heparin-
Sepharose column,
lane 3 = pool of lipoprotein lipase active fractions from w-amino-
phenylboronic acid agarose column,
lane 4 = lipoprotein lipase protein after preparative SDS-PAGE,
The gel was stained with Coomassie blue R 250 and Western blot
analysis was carried out as described in Methods. Known molecu-
lar mass protein markers are shown on the far left.
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intravenous injection of heparin, or with any other serum
proteins (data not shown).
Standardisa t ion of the ELISA method
Figure 2 illustrates the standard curve of the ELISA as-
say. The preparatively purified lipoprotein lipase was
used as a calibrator standard (see above: The purity of
lipoprotein lipase). Lipoprotein lipase standard was frac-
tionated into 100 μΐ and stored at -70 °C. A new aliquot
of the standard was thawed for each assay. The standard
curve for calibration was obtained by plotting the absor-
bance at 492 nm as a function of the standard lipopro-
tein lipase concentration. The standard curve shows a
good response down to 10 μ§/1, with an ideal working
range from 10 μg/l to 50 μg/l. Each standard point repre-
sents the mean ± SD of five different measurements.
Stability of standard l ipoprotein lipase and
postheparin plasma samples
The effects of freezing at -70 °C and thawing on the
stability of the lipoprotein lipase standard and human
postheparin plasma samples were investigated. The post-
heparin plasma lipoprotein lipase mass concentration of
ten fresh samples were measured and then subsequently
subjected to four freezing and thawing cycles. The sam-
ples' longest storage time was 12 months. Camparing
the fresh and thawed samples, the lipoprotein lipase con-
centrations of the purified lipoprotein lipase standard
and postheparin plasma samples differed by less than
5%. These results indicate that at least four freezing-
thawing cycles or one year's storage of the samples at
—70 °C did not affect lipoprotein lipase mass quantita-
tion with the ELISA-method.
The effects of storing the lipoprotein lipase standard and
postheparin plasma samples at + 4 °C were also studied.
The mass of the lipoprotein lipase standard remained
constant during storage, whereas postheparin plasma li-
poprotein lipase mass concentrations varied widely. In
most samples, lipoprotein lipase mass levels were higher
than in fresh plasma (data not shown). This may indicate
that postheparin plasma lipoprotein lipase protein un-
dergoes partial conformational change or degradation
during storage at + 4 °C, causing an increased immuno-
reactivity. It is therefore suggested that the measurement
of lipoprotein lipase immunoreactive mass be performed
in fresh samples or samples stored at -70 °C.
Validation of ELISA for lipoprotein lipase
mass quantitation
The validation of ELISA for lipoprotein lipase mass
quantitation was examined by precision and sample di-
lution analysis. Postheparin plasma from five subjects
was fractioned into aliquots of 100 μΐ before freezing
and were stored at -70 °C. Five plasma samples were
then analysed a total of ten times in the same assay
(twice per week for five weeks) to calculate the assay
precision. For inter-assay measurements, a new aliquot
of postheparin plasma was thawed each time. The mean
intra-assay and inter-assay coefficients of variation (CV)
for the whole working range of the ELISA assay were
5.1% and 6.5%, respectively.
Dilution studies were carried out using five different
postheparin plasma samples containing high, medium,
and low mass concentrations of lipoprotein lipase. All
samples were serially diluted (1 :40, 1 : 80, 1 : 160,
1 :320, 1 : 640). In all samples, linear dose-response
Lipoprotein lipase mass [μ9/Ι]
Fig. 2 The ELISA standard curve of lipoprotein lipase mass con-
centration determination. The immunoreactive mass of lipoprotein
lipase was measured by ELISA using a combination of polyclonal
and monoclonal antihuman lipoprotein lipase antibodies. Each
point represents the mean ± SD of five different measurements.
Both logarithmic and linear standard curves are presented.
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Fig. 3 Regression analysis between the ELISA method and a commercial EIA method.
Postheparin plasma samples were analysed and compared.
curves were obtained within the range of standard lipo-
protein lipase (0—70 μ£/1). The correlation of these mea-
surements was good (r = 0.94 ± 0.04, mean ± SD).
Comparison of ELISA and commercial EIA
assays
The correlation of the two methods was performed by
analysing postheparin plasma samples with varying lipo-
protein lipase concentrations. The regression between
the two techniques has a correlation coefficient of 0.81,
represented by the equation y = 2.58x + 51 (fig. 3). Ac-
cordingly, the correlation was good, although the ELISA
method gave significantly higher values than the com-
mercial one.
Lipoprotein lipase protein mass concentrat ion
and activity concentration in heal thy subjects
Lipoprotein lipase activity concentrations and mass in
postheparin plasma in healthy Finns were measured with
ELISA and EIA (tab. 1). The values showed no signifi-
cant differences between genders although women
tended to have slightly higher levels. Differences in lipo-
protein lipase concentration levels between the two as-
says is notable and will be discussed. The correlations
between lipoprotein lipase activity concentration and
mass concentration in healthy Finns (n = 66) are shown
in figure 4. Panel A represents the ELISA method, and
panel Β represents the commercial EIA method. A sig-
nificant, positive correlation existed between lipoprotein
lipase activity concentration and mass concentration in
both assays (for ELISA, r = +0.61, p < 0.001, for EIA
r = -f 0.71, p < 0.001). To calculate whether the corre-
lation varied for low and high lipoprotein lipase values
in the ELISA method, the individuals were divided into
groups according to their level of lipoprotein lipase cata-
lytic activity concentration. Group I (low lipoprotein li-
pase activity concentration) consisted of those subjects
with lipoprotein lipase activity concentration below 200
U/l (n = 15), and group II (high lipoprotein lipase activ-
ity concentration) consisted of the individuals with lipo-
protein lipase activity concentration over 300 U/l
(n = 19). In both groups, a significant positive correla-
tion existed (r = +0.63, p < 0.01 for group I, and
r = +0.73, p < 0.001 for group II) between lipoprotein
lipase activity concentration and mass concentration.
Discussion
In the present study we demonstrate the development of
the ELISA method for the determination of the immuno-
reactive mass of lipoprotein lipase in postheparin

































Ο 400 800 1200 1600 2000
Lipoprotein lipase (jig/TJ
Fig. 4 Correlations of postheparin plasma lipoprotein lipase cata-
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were found in healthy Finnish individuals (n = 66) using the
ELISA (A) and EIA (B) methods.
plasma. The study describes the immunisation protocol
of hens with semi-purified human milk lipoprotein li-
pase and purification of polyclonal anti-lipoprotein li-
pase antibodies. The monospecificity of the resulting
polyclonal antibody was ascertained by the Western
blotting technique.
Purifying of lipoprotein lipase enzyme to homogeneity
presents certain problems. The content of lipoprotein li-
pase in human physiological sources is very low. The
use of human milk as lipoprotein lipase enzyme source
is justified since human milk is rich in lipoprotein lipase
enzyme (18). The heparin-Sepharose and w-aminophe-
nylboronic acid agarose chromatographies were chosen
for the purification steps. The selection was based on
the studies by Uttsi-Oukari et al. (19) who showed these
chromatographies to be preferential for purifying lipo-
lytic enzymes from postheparin plasma. After the hepa-
rin-Sepharose affinity and w-aminophenylboronic acid
agarose chromatographies the preparation of human
milk lipoprotein lipase contained at least two proteins.
This preparation is pure enough for immunisation
purposes but cannot be used as a calibrator standard in
the ELISA assay. Gel filtration, phenyl-Sepharose and
the use of a salt gradient (from 0.4 to 2 mol/1 NaCl) in
the heparin-Sepharose affinity chromatography failed to
separate the lipoprotein lipase protein and contaminating
protein present in the m-aminophenylboronic acid pool
(fig. 1, lane 3). Preparative gel electrophoresis was
therefore selected as the final purification method to
produce the lipoprotein lipase standard for calibrating
the ELISA method. The final preparation contained lipo-
protein lipase protein, which reacted well with both
polyclonal and monoclonal antihuman lipoprotein li-
pase antibodies.
Analytical ultracentrifiigation studies (26, 27) and a
study using radiation inactivation (28) of purified lipo-
protein lipase obtained from bovine milk indicated that
the active lipoprotein lipase is a non-covalent homo-di-
mer glycoprotein (4). To measure total lipoprotein lipase
mass concentration, including both monomeric and di-
meric protein forms with immunological assays, either
two different monoclonal antibodies or a combination of
polyclonal and monoclonal antibodies is required. The
present ELISA method uses a polyclonal antibody for
capture and a monoclonal antibody as a detection anti-
body. Good sensitivity was achieved down to lipoprotein
lipase mass concentrations of 10 \ig/l. The precision of
the ELISA method was also good.
In the healthy Finnish subjects studied, there was a wide
range of both lipoprotein lipase activity concentration
and mass concentration in postheparin plasma. Both the
ELISA method and a commercially available EIA kit for
the quantitation of lipoprotein lipase mass concentration
in plasma are sensitive; a good correlation existed be-
tween lipoprotein lipase activity concentration and mass
concentration for both low and high values. The calcu-
lated specific activity (U/^g) is therefore uniform, and
changes in this property can be used as a good tool to
follow certain abnormalities in lipoprotein lipase metab-
olism.
The different levels in lipoprotein lipase mass concentra-
tions found in two described methods may be due to the
different antibodies and/or the primary standardisation
of the assay. A relative good correlation between the
two assays, however, suggests that the main contributor
is a primary standardisation. Lipoprotein lipase protein
in the samples, or in the primary or calibrator standards,
may change its conformation during storage or thawing.
This may have an major effect on the reactivity with
anti-lipoprotein lipase antibodies and the shape of cali-
bration curves. In all immunoassays using one or two
different monoclonal anti-lipoprotein lipase antibodies,
the reference values for postheparin plasma lipoprotein
lipase in healthy individuals ranged from 200 to 400 μg/l
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(11, 12, 15). The assays with a combination of affinity-
purified polyclonal and monoclonal antibody, however,
measure higher postheparin plasma lipoprotein lipase
mass concentrations, the mean values being 800-1000
μg/l ((13), the present ELISA assay). In the previously
described immunoassays (8-12), the primary or calibra-
tor standards were not described in detail, except in the
method described by Ideda et al. (15). In addition, the
validation of these methods for lipoprotein lipase quanti-
tation was poorly defined. At present, no international
standards exist for lipoprotein lipase, which makes the
comparison of results between different assays and
laboratories impossible. Present standardisation efforts
need to be directed toward removing sources of variabil-
ity in laboratory methods through the use of certified
reference material for calibration. For these reasons, a
need for well-defined primary or calibrator standards
and reference values is justified for studies in which li-
poprotein lipase catalytic activity concentrations and
mass concentrations are measured.
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